NHS Introduces Fampridine to Enhance Mobility for Multiple Sclerosis Patients
The National Health Service (NHS) in England has begun the rollout of a new drug, fampridine, which is expected to significantly improve walking ability for patients with multiple sclerosis (MS). Fampridine, also known as Fampyra, acts as a signal booster within the nervous system, helping to restore electrical signals along damaged nerves. This enables muscles to function more effectively, thereby improving overall mobility for MS patients. The drug is particularly targeted at those with certain scores on the Expanded Disability Status Scale (EDSS), which measures disability caused by MS. Patients will trial the drug for two to four weeks, with their walking ability assessed before and after treatment. If progress is observed, they will continue the medication with regular reviews. Fampridine has shown to improve walking speed in 43% of patients during trials. 
